Learn About Sertoli-Leydig Cell Tumor

What is the definition of Sertoli-Leydig Cell Tumor?

Sertoli-Leydig cell tumor (SLCT) is a rare cancer of the ovaries. The cancer cells produce and release a male sex hormone called testosterone.

What are the alternative names for Sertoli-Leydig Cell Tumor?

Sertoli-stromal cell tumor; Arrhenoblastoma; Androblastoma; Ovarian cancer - Sertoli-Leydig cell tumor

What are the causes of Sertoli-Leydig Cell Tumor?

The exact cause of this tumor is not known. Changes (alterations) in genes may play a role.

SLCT occur most often in young women 20 to 30 years old. But the tumor can occur at any age.

What are the symptoms of Sertoli-Leydig Cell Tumor?

The Sertoli cells are normally located in the male reproductive glands (the testes). They feed sperm cells. The Leydig cells, also located in the testes, release a male sex hormone.

These cells are also found in a woman's ovaries, and in very rare cases lead to cancer. SLCT starts in the female ovaries, mostly in one ovary. The cancer cells release a male sex hormone. As a result, the woman may develop symptoms such as:

  • A deep voice
  • Enlarged clitoris
  • Facial hair
  • Loss in breast size
  • Stopping of menstrual periods

Pain in the lower belly (pelvic area) is another symptom. It occurs due to the tumor pressing on nearby structures.

Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Sertoli-Leydig Cell Tumor?

Surgery is done to remove one or both ovaries.

If the tumor is at an advanced stage, chemotherapy or radiation therapy may be done after surgery.

Who are the top Sertoli-Leydig Cell Tumor Local Doctors?
Advanced in Sertoli-Leydig Cell Tumor
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Sertoli-Leydig Cell Tumor
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Allegheny Clinic

4815 Liberty Ave, Suite 310, 
Pittsburgh, PA 
 (15.0 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

John Nakayama is a Gynecologic Oncologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Nakayama and is rated as an Advanced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Lump in the Abdomen, Oophorectomy, and Hysterectomy. Dr. Nakayama is currently accepting new patients.

Experienced in Sertoli-Leydig Cell Tumor
Hematology Oncology | Oncology
Experienced in Sertoli-Leydig Cell Tumor
Hematology Oncology | Oncology
1600 Coraopolis Heights Rd, Suite F, 
Moon Township, PA 
 (1.4 mi)
Languages Spoken:
English

Michael Sherry is a Hematologist Oncology specialist and an Oncologist in Moon Township, Pennsylvania. Dr. Sherry and is rated as an Experienced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Pulmonary Embolism, Paget Disease of the Breast, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Familial Colorectal Cancer.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Sertoli-Leydig Cell Tumor
Obstetrics and Gynecology | Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Obstetrics and Gynecology | Oncology

University Of Pittsburgh Physicians

300 Halket St, Suite 1750, 
Pittsburgh, PA 
 (14.8 mi)
Languages Spoken:
English, Arabic
Accepting New Patients

Haider Mahdi is an Obstetrics and Gynecologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Mahdi and is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Mahdi is currently accepting new patients.

What is the outlook (prognosis) for Sertoli-Leydig Cell Tumor?

Early treatment results in a good outcome. Feminine characteristics usually return after surgery. But male characteristics resolve more slowly.

For more advanced stage tumors, outlook is less positive.

What are the latest Sertoli-Leydig Cell Tumor Clinical Trials?
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Summary: This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Background: - Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in children younger than 6 years of age. Recently, it has been shown that this condition can be inherited (e.g., mutation of the DICER1 gene). Researchers are studying both clinical and genetic aspects of this newly described condition. They are interested in...

Who are the sources who wrote this article ?

Published Date: June 17, 2024
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Beffa LB, Sung CJ, DiSilvestro PA. Germ cell, stromal, and other ovarian tumors. In: Creasman WT, Mutch DG, Mannel RS, Tewari KS, eds. DiSaia and Creasman Clinical Gynecologic Oncology. 10th ed. Philadelphia, PA: Elsevier; 2023:chap 10.

Fletcher CDM. Tumors of the female genital tract. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 5th ed. Philadelphia, PA: Elsevier; 2021:chap 13.

Smith RP. Sertoli-Leydig cell tumor (arrhenoblastoma). In: Smith RP, ed. Netter's Obstetrics & Gynecology. 4th ed. Philadelphia, PA: Elsevier; 2024:chap 165.